Trevi Therapeutics (TRVI) Total Debt (2020 - 2023)

Trevi Therapeutics has reported Total Debt for 4 years, with the latest figure at $7.5 million in Q1 2023.

• For the quarter ending Q1 2023, Total Debt fell 46.77% year-over-year to $7.5 million; the trailing twelve-month figure through Mar 2023 stood at $7.5 million (down 46.77% YoY), and the FY2022 full-year result was $9.2 million, down 36.82% from the prior year.
• Total Debt for Q1 2023 stood at $7.5 million, down from $9.2 million in the prior quarter.
• The five-year high for Total Debt was $14.5 million in Q4 2021, with the low at $7.5 million in Q1 2023.
• Average Total Debt over 4 years is $12.6 million, with a median of $14.0 million recorded in 2020.
• Year-over-year, Total Debt advanced 3.84% in 2021 and sank 46.77% in 2023.
• Tracing TRVI's Total Debt over 4 years: stood at $14.0 million in 2020, then increased by 3.81% to $14.5 million in 2021, then tumbled by 36.82% to $9.2 million in 2022, then fell by 18.24% to $7.5 million in 2023.
• The last three Total Debt figures came in at $7.5 million (Q1 2023), $9.2 million (Q4 2022), and $10.8 million (Q3 2022), per Business Quant data.

Peer Comparison